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Background: Due to the low incidence of thymoma, there is little 
high-quality evidence on the clinical management of thymoma. Much 
of the evidence consists of small retrospective case series. As a result, 
in 2006, a working group of the provincial Lung Disease Site Group 
undertook a formal consensus process to develop a guideline for the 
management of malignant thymoma through Cancer Care Ontario’s 
Program in Evidence-based Care (PEBC).
Methods: The consensus process followed a traditional evidence-based 
guideline development process, beginning with a systematic search of 
the literature and a review of evidence. Members of the DSG reviewed 
the studies available from 1996 onwards and and met in two teleconfer-
ences to draft preliminary recommendations. A modiﬁed-Delphi formal 
consensus process was then undertaken. The draft recommendations 
were distributed as a survey to a sample of relevant clinicians from 
across Canada (n=68) for two rounds of response. Round one entailed 
respondents reviewing a brief evidence summary, with instructions 
to rate their degree of agreement or disagreement (scale 1 to 7, 1 = 
strongly agree, 7 = strongly disagree) for each of the 38 thymoma man-
agement recommendations proposed by the Lung DSG working group. 
Results: In Round One, responses were received from 32/68 (47%) of 
individuals surveyed. Of the 38 recommendations, 9 were identiﬁed 
as having signiﬁcant variability in agreement amongst reviewers. In 
Round Two, a statistical and graphical representation of results from 
Round One were distributed, and respondents were asked to re-rate 
their agreement with recommendations, in consideration of the group 
responses. For some items respondents articulated possible changes 
to the recommendations in their written feedback. These were incor-
porated in the Round Two questionnaire as ‘options’, and respondents 
were asked to identify their agreement with the original and with the 
modiﬁed second recommendation. 
Conclusion: The results from Round Two are pending; the working 
group will reconvene via teleconference to conﬁrm that issues of prior 
disagreement have been appropriately addressed, and/or made explicit 
in the ﬁnal report. Final consensus guideline recommendations will be 
presented.
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Asbestos and mesothelioma in egypt
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Background: The widespread use of asbestos during the 20th century 
has produced a legacy of ill-health, death and contamination which will 
endure well into the current century. Epidemics of asbestos illness have 
been reported in industrialized countries for many years; now, data 
are being collated which document an escalation of these diseases in 
developing countries such as Brazil, Thailand and Egypt.
Asbestos manufacturing began in Egypt more than 50 years ago. By 
2004, there were 14 asbestos factories employing thousands of work-
ers. Asbestos is imported from Russia and Canada and is used for the 
manufacture of asbestos-cement pipes, rooﬁng and wall materials, 
valves, joints, sealants, clothing, cords, strings, clutches, brake linings 
and pads; crocidolite and amosite were used in pipes and corrugated 
sheets until fairly recently. The working conditions in these factories 
were poor and included occupational exposure to various asbestos 
types on a daily basis.
Methods and Results: In the ﬁrst 5 years of the 3rd millennium 
(2000-2004), 832 cases of mesothelioma were diagnosed at NCI, and 
Abbassia Chest Hospital, Cairo. Both hospitals drain and serve most 
of the high risk population living in the neighborhoods of the oldest 
asbestos production plants. Median age was 53 (19-90) years. Females 
represented 39.2% and young adults ≤ 40 years represented 19.1%. 
Residential exposure was evidenced in 64.7% of cases (Shobra El-
khema, 35.6%, El-Maasara and surrounding area 23.6%, El Zytoon 
5.2%, and others 0.5%). Twenty ﬁve percent came from other Cairo 
areas and 9.8% from other governorates. The NCI hospital based-reg-
istry showed an increase in the relative frequency of MPM from 0.47% 
in 2001, to 1.4% in 2004.
In a trial to ﬁnd a relation between residency and asbestos exposure, 
a ﬁeld study was done to investigate the residential areas surrounding 
the oldest factory in El-Maasara, Cairo. Heaps of asbestos wastes with 
breaks of cement pipes and sheets were visualized outside the fence 
of the factory, improperly disposed off. Repeated airborne asbestos 
samples were collected using National Institute for Occupational Safety 
and Health (NIOSH) method No 7400. Results showed the presence of 
asbestos ﬁbers in those residential areas in counts ranging from 0.002 
f/cc, 7 kilometers from the factory, to levels beyond permissible expo-
sure limits and excursion limit (3.02 f/cc) few meters from the factory. 
Although the Egyptian Minister of Foreign Trade and Industry prohib-
ited the import and manufacture of all types of asbestos and asbestos 
materials in 2006, it is believed that chrysotile is still being used in the 
manufacture of asbestos-cement materials. 
The NCI, Cairo recommendations include periodic monitoring of the 
environment inside and outside the factories for permissible exposure 
limits (PEL), increasing awareness of the public regarding the risk of 
asbestos exposure, education and protection of Egyptian asbestos work-
ers, follow up and if possible periodical medical checks for population 
at risk of occupational and/or residential exposure.
Conclusion: There is a clear need for stronger legislative measures to 
eliminate asbestos entirely in order to combat the coming epidemic of 
mesothelioma in Egypt. 
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